MARKHAM, ON, June 1, 2012 /CNW/ - Cytochroma today announced that it has
regained the rights to all indications in the United States (US) and in
Asian territories to lunacalcipol (previously known as CTA018) through
the termination of a license agreement between Cytochroma and
Mitsubishi Tanabe Pharma Corporation ("MTPC"). MTPC and Cytochroma
mutually decided to suspend further development of lunacalcipol
injection based on changing US market dynamics.
"We are disappointed at the ending of our lunacalcipol collaboration
with Mitsubishi Tanabe, and are grateful for their strong support and
partnership over the last few years," stated Dr. Charles W. Bishop,
President and CEO of Cytochroma. "Lunacalcipol has shown great promise
as a new treatment for secondary hyperparathyroidism without the
calcemic side effects seen with existing vitamin D hormone therapies.
But, unfortunately, recent restrictions in government reimbursement for
drugs used in US dialysis patients make the continued development of
lunacalcipol injection for that patient population financially
unsustainable. Our primary focus continues to be moving forward with
Phase 3 trials of our lead product, CTAP101 Capsules, which is under
development for secondary hyperparathyroidism in patients with vitamin
D insufficiency and stage 3 or 4 chronic kidney disease, a patient
population wherein drug reimbursement dynamics are much more
In July 2008, Cytochroma and MTPC signed a license agreement under which
Cytochroma granted MTPC an exclusive license in the US and Asia,
including Japan, to develop and commercialize lunacalcipol.
Lunacalcipol is the first compound in a new class of vitamin D hormone
analogs having a novel dual mechanism of action. Lunacalcipol is
designed to be a strong activator of the vitamin D signaling pathway as
well as a potent inhibitor of CYP24, the intracellular enzyme
responsible for the catabolism of vitamin D hormones.
Cytochroma is a clinical stage specialty pharmaceutical company focused
on developing and commercializing proprietary products to treat and
prevent the clinical consequences of vitamin D insufficiency and
secondary hyperparathyroidism (SHPT) associated with chronic kidney
disease (CKD). The Company specializes in developing new therapies
which are designed to safely and effectively treat patients with stage
3, 4 and 5 CKD. Cytochroma also has a portfolio CYP24 and
phosphate-uptake inhibitors in early stage development.
For more information about Cytochroma, please visit www.cytochroma.com.
For further information:
Executive Director, Corporate Development
Tel: +1 (905) 479-5306 ext. 333
Robert Stanislaro (FTI Consulting)
Tel: +1 (212) 850-5657